Jefferson Arturo Guzman

Prof. Jefferson Arturo Guzman

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2025 in Revista GEN
Verified
Journal Article
Open access
PDF file
MGMaría Fatima Garcés
María Fatima Garcés
JGJefferson Arturo Guzman
Jefferson Arturo Guzman
XMXiomara Moreno
Xiomara Moreno
AMAna Cecilia Márquez
Ana Cecilia Márquez
KLKarolina López
Karolina López
YSYacelli Bustamante Siberio
Yacelli Bustamante Siberio
Introducción: La disbiosis en niños con trastornos del espectro autista (TEA), puede inducir inflamación intestinal y alteraciones en la permeabilidad intestinal favoreciendo la presencia de manifestaciones gastrointestinales y neuroconductuales. Objetivo: Evaluar la relación que existe entre la disbiosis y los niveles fecales de zonulina y calprotectina en niños con TEA. Métodos: Los niveles de zonulina fueron evaluados mediante la técnica de inmunoensayo enzimático ligado a enzima (ELISA), calprotectina fecal por Turbidimetria y la disbiosis por el método de cultivo, en una cohorte de 40 niños con TEA y 18 niños normotípicos. Resultados: El 95% de los pacientes con TEA estudiados presentaron disbiosis intestinal. Un 65 % de los pacientes con disbiosis tenían niveles elevados de zonulina y/o calprotectina fecal. Se encontraron niveles elevados de zonulina fecal en 15% de los pacientes con TEA obteniendo un valor mediano de 44,5 (IQR=43,0) ng/mL en el grupo TEA y de 42,0 (IQR=19,0) ng/mL en el grupo control, sin diferencias significativas entre los dos grupos. Se encontraron niveles elevados de calprotectina fecal en el 60 % de los pacientes con TEA, obteniendo un valor mediano de 75,0 (IQR= 127,3) μg/g y en el grupo control de 21,0 (IQR=23,5) μg/g, siendo significativamente mayor la distribución de calprotectina en los pacientes con TEA que en el grupo control (W = 116,5, p<0,001). Conclusión: Se observó una relación entre la disbiosis, los síntomas gastrointestinales y los niveles elevados de calprotectina fecal en pacientes con TEA.ESCUCHE EL RESUMEN HANCIENDO CLIC EN EL IDIOMA DE SU PREFERENCIA:EspañolEnglishPortugues

7 September 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
MGMaría Fatima Garcés
María Fatima Garcés
JGJefferson Arturo Guzman
Jefferson Arturo Guzman
DADaniel A Aranguren Aranguren
Daniel A Aranguren Aranguren
LFLina Figueira
Lina Figueira
RBRicardo Blanch
Ricardo Blanch
APAlexis Hipolito García Piñero
Alexis Hipolito García Piñero
Genotype-resolved data on human papillomavirus (HPV) are almost absent for Venezuelan indigenous populations. We conducted a multi-site cross-sectional study of 260 indigenous women from La Guajira (Wayuu, n = 94), Maniapure (Eñepa, n = 141), and Delta Amacuro (Warao, n = 25), Venezuela. All samples were processed under a single protocol, with real-time PCR resolving 21 genotypes individually; conventional cytology was available in 144 women. Overall HPV prevalence was 55.4% (95% CI 49.3–61.3) and high-risk HPV prevalence was 51.2% (95% CI 45.1–57.2); positivity differed across communities (χ² = 13.40, df = 2, p = 0.001), reaching 80.0% in Delta Amacuro versus 59.6% in Maniapure and 42.6% in La Guajira. Nineteen genotypes were detected. HPV-31 was the most frequent overall (15.8%), then HPV-16 (11.5%) and HPV-18 (9.2%). The profiles differed markedly between communities: HPV-68 (48.0%) and HPV-56 (40.0%) in Delta Amacuro, HPV-51 (9.6%) in La Guajira, and HPV-31 (20.6%) in Maniapure. Multiple genotypes were found in 51.4% of infected women. Agreement between cytology and qPCR was negligible (Cohen’s κ = 0.056), with a cytology sensitivity of 25.6%. HPV is highly prevalent in these communities; the circulating genotype spectrum extends well beyond HPV-16/18, and cytology alone is not an adequate screening strategy. In conclusion, the nonavalent vaccine is preferred, as it covers 69.4% of infected women of the indigenous community, compared to 30.6% for the bivalent formulation.

19 October 2026 in Diseases
Verified
Journal Article
Open access
PDF file
MGMaría Fatima Garcés
María Fatima Garcés
JGJefferson Arturo Guzman
Jefferson Arturo Guzman
DADaniel A Aranguren Aranguren
Daniel A Aranguren Aranguren
LFLina Figueira
Lina Figueira
RBRicardo Blanch
Ricardo Blanch
APAlexis Hipolito García Piñero
Alexis Hipolito García Piñero
Background: Genotype-resolved data on human papillomavirus (HPV) are almost absent for Venezuelan indigenous women. Methods: We studied 260 women from La Guajira (Wayuu, n = 94), Maniapure (Eñepa, n = 141), and Delta Amacuro (Warao, n = 25), processing all self-collected samples with a single real-time PCR assay that resolves 21 genotypes; cytology was available for 144. Results: HPV prevalence was 55.4% (95% CI 49.3–61.3) and high-risk prevalence was 51.2% (95% CI 45.1–57.2), rising from 42.6% in La Guajira to 59.6% in Maniapure and 80.0% in Delta Amacuro (p = 0.001). Nineteen genotypes were detected. HPV-31 was most frequent (15.8%), followed by HPV-16 (11.5%), and each community had its own profile, with HPV-68 and HPV-56 leading in Delta Amacuro. Half of the infected women carried more than one type. Cytology and HPV testing overlapped little: 20 of 78 HPV-positive women with a smear (25.6%) had an abnormal result (κ = 0.056). At least one nonavalent vaccine type was present in 69.4% of infected women, compared with 30.6% for the bivalent vaccine. Conclusions: HPV vaccination is not part of the Venezuelan national program; these data favor the nonavalent formulation, and HPV-based screening would need a feasible triage pathway for the many women who test positive.